Literature DB >> 2219960

Absorption, distribution and excretion of lacidipine, a dihydropyridine calcium antagonist, in rat and dog.

M Pellegatti1, P Grossi, J Ayrton, G L Evans, A J Harker.   

Abstract

1. The absorption, distribution and excretion of lacidipine have been studied in rat and dog after i.v. (0.05 mg/kg for rat; 0.5 mg/kg for dog) and oral dosage (2.5 mg/kg for rat; 2.0 mg/kg for dog). 2. Lacidipine was rapidly and extensively absorbed after oral dosing, in both species. Oral bioavailability was up to 26% in rat and up to 32% in dog, due to extensive first-pass metabolism. 3. After oral administration, peak levels of radioactivity were reached at 4-8 h in rat and 1-2 h in dog. Unchanged lacidipine peaked at 1-2 h in both species. Plasma levels of radioactivity were higher in female rats than in males but there was no difference in levels of unchanged drug. 4. After i.v. dosing the terminal half-life of unchanged drug was 2.9 h in rat and 8.2 h in dog. The half-life of radioactivity in plasma was longer in both species. 5. After both routes of administration, radioactivity was rapidly distributed in rat tissues with the highest concentration in liver, fat and gastrointestinal tract. Only traces of radioactivity were detected in the CNS and in rat foetuses. 6. Extensive biliary elimination occurred, and most of the radioactivity (73-95%) was excreted in the faeces after i.v. or oral administration. 7. The compound was extensively metabolized, no significant amount of unchanged drug was excreted in bile or urine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2219960     DOI: 10.3109/00498259009046891

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  5 in total

Review 1.  Factors influencing the bioavailability of peroral formulations of drugs for dogs.

Authors:  S Sabnis
Journal:  Vet Res Commun       Date:  1999-11       Impact factor: 2.459

Review 2.  Lacidipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension.

Authors:  C R Lee; H M Bryson
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

3.  Quality risk management of top spray fluidized bed process for antihypertensive drug formulation with control strategy engendered by Box-behnken experimental design space.

Authors:  Amit Mukharya; Paresh U Patel; Dinesh Shenoy; Shivang Chaudhary
Journal:  Int J Pharm Investig       Date:  2013-01

4.  Effect assessment of "film coating and packaging" on the photo-stability of highly photo-labile antihypertensive products.

Authors:  Amit Mukharya; Paresh U Patel; Shivang Chaudhary
Journal:  Int J Pharm Investig       Date:  2013-04

5.  Solid-state characterization of lacidipine/PVP K(29/32) solid dispersion primed by solvent co-evaporation.

Authors:  Amit Mukharya; Shivang Chaudhary; Niyaz Mansuri; Arun K Misra
Journal:  Int J Pharm Investig       Date:  2012-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.